V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

MacroGenics Executive Compensation (FY25)

MGNX · Executive and director compensation, fiscal 2024 to 2025

The MacroGenics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 21, 2026Latest filing (8-K): May 20, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
MacroGenics brief$1,500Get the executive brief
189 figures on this page: 178 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Eric Risser
Latest say-on-pay support
=
May 19, 2026
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Scott Koenig → Eric Risser

Frequently asked questions

Answers drawn from the data on this page.
Who is MacroGenics' chief executive and what were they paid?
Eric Risser was paid $2,078,854 in total compensation as President, Chief Executive Officer and Director for fiscal 2025.
What was MacroGenics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.1% of votes cast for or against in favor at the meeting held May 19, 2026.
Which companies are in MacroGenics' peer group?
The disclosed peer group includes 2seventy bio, Adaptimmune Therapeutics, Agenus, Inc., Arcus Biosciences and Cogent Biosciences, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Scott Koenig
Former Chief Executive Officer and current Director
◇—◇◇◇—◇◇
James Karrels
Senior Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Risser
President, Chief Executive Officer and Director
◇◇◇◇◇—◇◇
Ezio Bonvini
Senior Vice President, Research and Chief Scientific Officer
◇◇◇◇◇—◇◇
James Karrels
Senior Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Scott Koenig
Former Chief Executive Officer and current Director
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James KarrelsOption◇—◇2/7/2035
Option◇—◇2/8/2034
Option◇—◇2/15/2033
Option◇—◇2/22/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Ezio BonviniOption◇—◇2/7/2035
Option◇—◇2/8/2034
Option◇—◇2/22/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2023
Scott KoenigOption◇—◇2/8/2034
Option◇—◇2/15/2033
Option◇—◇2/22/2032
RSU◇◇——
RSU◇◇——
Eric RisserOption◇—◇8/13/2035
Option◇—◇2/7/2035
Option◇—◇2/8/2034
Option◇—◇2/15/2023
Option◇—◇2/22/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Ezio Bonvini
Senior Vice President, Research and Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Scott Koenig
Former Chief Executive Officer and current Director · Severance agreement
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Heiden
◇◇◇———◇
Federica O'Brien
◇◇◇———◇
Jay Siegel
◇◇◇———◇
David Stump
◇◇◇———◇
Margaret Liu
◇◇◇———◇
Edward Hurwitz
◇◇◇———◇
Karen Ferrante
◇◇◇———◇
Scott Jackson
◇◇◇———◇
Meenu Chhabra Karson
◇◇◇———◇
Scott Koenig
◇—————◇
Eric Risser served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 2seventy bio TSVT
  • Adaptimmune Therapeutics ADAP
  • Agenus, Inc. AGEN
  • Arcus Biosciences RCUS
  • Cogent Biosciences COGT
  • Fate Therapeutics FATE
  • G1 Therapeutics symbol not shown
  • Inovio Pharmaceuticals INO
  • iTeos Therapeutics ITOS
  • Karyopharm Therapeutics KPTI
  • Mersana Therapeutics MRSN
  • Precigen PGEN
  • Rigel Pharmaceuticals RIGL
  • Xencor, Inc. XNCR
  • Y-mAbs Therapeutics YMAB
  • Zymeworks, Inc. ZYME

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2024May 21, 2025=◇◇◇
2023May 21, 2024=◇◇◇
2022May 31, 2023=◇◇◇
2021May 19, 2022=◇◇◇
2020May 13, 2021=◇◇◇
2019May 14, 2020=◇◇◇
2018May 16, 2019=◇◇◇
2017May 17, 2018=◇◇◇
2016May 18, 2017=◇◇◇
2015May 18, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when MacroGenics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact MacroGenics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where MacroGenics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether MacroGenics' disclosed peer group is defensible, who names MacroGenics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
189 figures on this page: 178 cited to the filing that reported them, 11 calculated from figures it prints.
178 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001125345-26-000042
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001125345-26-000021
    Compensation Discussion and Analysis · Director Compensation · Summary Compensation Table
  3. 0001125345-25-000075
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001125345-25-000047
    Summary Compensation Table
  5. 0001125345-25-000042
    Exhibit
  6. 0001125345-24-000124
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001125345-23-000081
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001125345-22-000053
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001125345-21-000082
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001125345-20-000079
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001125345-19-000081
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001125345-18-000077
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001125345-17-000062
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001125345-16-000059
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “MacroGenics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/MGNX (accessed 2026).
Short form: data: Velarion

The MacroGenics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about MacroGenics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers MacroGenics discloses

The companies named in MGNX's own disclosed peer group.

Adaptimmune TherapeuticsAgenus, Inc.Arcus BiosciencesCogent BiosciencesFate TherapeuticsInovio PharmaceuticalsiTeos TherapeuticsKaryopharm TherapeuticsMersana TherapeuticsPrecigenRigel PharmaceuticalsXencor, Inc.Y-mAbs TherapeuticsZymeworks, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy